219 related articles for article (PubMed ID: 11168640)
21. Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered.
Esquivel-Pérez R; Moreno-Fierros L
Viral Immunol; 2005; 18(4):695-708. PubMed ID: 16359236
[TBL] [Abstract][Full Text] [Related]
22. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
Zhang P; Lewis JP; Michalek SM; Katz J
Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
[TBL] [Abstract][Full Text] [Related]
23. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
[TBL] [Abstract][Full Text] [Related]
24. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
25. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
Maloy KJ; Donachie AM; O'Hagan DT; Mowat AM
Immunology; 1994 Apr; 81(4):661-7. PubMed ID: 7518802
[TBL] [Abstract][Full Text] [Related]
26. Per-oral immunization with antigen-conjugated nanoparticles followed by sub-cutaneous boosting immunization induces long-lasting mucosal and systemic antibody responses in mice.
Howe SE; Konjufca VH
PLoS One; 2015; 10(2):e0118067. PubMed ID: 25710518
[TBL] [Abstract][Full Text] [Related]
27. Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines.
Haugan A; Thi Dao PX; Glende N; Bakke H; Haugen IL; Janakova L; Berstad AK; Holst J; Haneberg B
Vaccine; 2003 Dec; 22(1):7-14. PubMed ID: 14604565
[TBL] [Abstract][Full Text] [Related]
28. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route.
Medina E; Talay SR; Chhatwal GS; Guzmán CA
Eur J Immunol; 1998 Mar; 28(3):1069-77. PubMed ID: 9541603
[TBL] [Abstract][Full Text] [Related]
29. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
Ishii M; Kojima N
Glycoconj J; 2010 Jan; 27(1):115-23. PubMed ID: 19816665
[TBL] [Abstract][Full Text] [Related]
30. Mucosal adjuvant properties of the Shigella invasin complex.
Kaminski RW; Turbyfill KR; Oaks EV
Infect Immun; 2006 May; 74(5):2856-66. PubMed ID: 16622224
[TBL] [Abstract][Full Text] [Related]
31. Modulation of oral tolerance to ovalbumin by cholera toxin and its B subunit.
Pierre P; Denis O; Bazin H; Mbongolo Mbella E; Vaerman JP
Eur J Immunol; 1992 Dec; 22(12):3179-82. PubMed ID: 1446708
[TBL] [Abstract][Full Text] [Related]
32. Fragilysin, the enterotoxin from Bacteroides fragilis, enhances the serum antibody response to antigen co-administered by the intranasal route.
Vines RR; Perdue SS; Moncrief JS; Sentz DR; Barroso LA; Wright RL; Wilkins TD
Vaccine; 2000 Nov; 19(6):655-60. PubMed ID: 11090718
[TBL] [Abstract][Full Text] [Related]
33. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N
Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476
[TBL] [Abstract][Full Text] [Related]
34. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.
Blanchard TG; Lycke N; Czinn SJ; Nedrud JG
Immunology; 1998 May; 94(1):22-7. PubMed ID: 9708182
[TBL] [Abstract][Full Text] [Related]
35. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice.
Shahiwala A; Amiji MM
J Drug Target; 2008 May; 16(4):302-10. PubMed ID: 18446609
[TBL] [Abstract][Full Text] [Related]
36. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
[TBL] [Abstract][Full Text] [Related]
37. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
Roberts M; Bacon A; Rappuoli R; Pizza M; Cropley I; Douce G; Dougan G; Marinaro M; McGhee J; Chatfield S
Infect Immun; 1995 Jun; 63(6):2100-8. PubMed ID: 7768587
[TBL] [Abstract][Full Text] [Related]
38. Impaired mucosal immune responses in interleukin 4-targeted mice.
Vajdy M; Kosco-Vilbois MH; Kopf M; Köhler G; Lycke N
J Exp Med; 1995 Jan; 181(1):41-53. PubMed ID: 7807021
[TBL] [Abstract][Full Text] [Related]
39. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
[TBL] [Abstract][Full Text] [Related]
40. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.
Stettin A; Schultze JL; Stechemesser E; Berg PA
Klin Wochenschr; 1990 Sep; 68(18):896-900. PubMed ID: 2124308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
